Analysts Set Expectations for Teladoc Health FY2026 Earnings

Teladoc Health, Inc. (NYSE:TDOC – Free Report) – Equities research analysts at Zacks Research boosted their FY2026 earnings per share estimates for Teladoc Health in a research report issued to clients and investors on Wednesday, November 18th. Zacks Research analyst Team now expects that the health services provider will post earnings of ($0.87) per share for the year, up from their prior forecast of ($0.89). The consensus estimate for Teladoc Health’s current full-year earnings is ($0.86) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.17) EPS, Q4 2027 earnings at ($0.25) EPS, FY2027 earnings at ($0.91) EPS, Q1 2028 earnings at ($0.17) EPS, Q3 2028 earnings at ($0.12) EPS and FY2028 earnings at ($0.64) EPS.

TDOC has been the topic of a number of other reports. TD Cowen increased their price objective on Teladoc Health from $6.00 to $8.00 and gave the company a “hold” rating in a research report on Monday, November 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a research report on Tuesday. Bank of America upped their price target on Teladoc Health from $10.50 to $11.50 in a research note on Thursday, October 29th. Argus lowered Teladoc Health from a “hold” rating to a “sell” rating in a research note on Monday, November 2nd. Finally, Citigroup decreased their price target on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.60.

Check Out Our Latest Analysis on Teladoc Health

Teladoc Health Price Performance

TDOC opened at $7.80 on Friday. The stock has a market capitalization of $1.42 billion, a P/E ratio of -9.08 and a beta of 2.00. The company’s 50 day simple moving average is $6.93 and its 200-day simple moving average is $6.66. Teladoc Health has a one year low of $4.40 and a one year high of $9.89.

Teladoc Health (NYSE:TDOC – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $605.10 million for the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The company’s revenue was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.28) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Algert Global LLC grew its stake in shares of Teladoc Health by 42.6% in the third quarter. Algert Global LLC now owns 203,810 shares of the health services provider’s stock valued at $1,182,000 after buying an additional 60,910 shares in the last quarter. Virtu Financial LLC increased its holdings in Teladoc Health by 40.4% during the third quarter. Virtu Financial LLC now owns 41,030 shares of the health services provider’s stock worth $238,000 after buying an additional 11,814 shares during the last quarter. New York State Common Retirement Fund raised its position in Teladoc Health by 22.7% during the third quarter. New York State Common Retirement Fund now owns 63,203 shares of the health services provider’s stock worth $367,000 after acquiring an additional 11,700 shares in the last quarter. Allworth Financial LP raised its position in Teladoc Health by 65.5% during the third quarter. Allworth Financial LP now owns 4,863 shares of the health services provider’s stock worth $28,000 after acquiring an additional 1,925 shares in the last quarter. Finally, FORA Capital LLC bought a new stake in Teladoc Health during the third quarter worth $425,000. 76.82% of the stock is currently owned by institutional investors.

Insider Activity

In other Teladoc Health news, insider Carlos Nueno sold 29,432 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $9.20, for a total value of $270,774.40. Following the sale, the insider owned 35,312 shares in the company, valued at approximately $324,870.40. The trade was a 45.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Charles III sold 17,805 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the transaction, the chief executive officer owned 465,535 shares of the company’s stock, valued at $2,839,763.50. The trade was a 3.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 47,892 shares of company stock worth $383,086 in the last three months. Company insiders own 0.70% of the company’s stock.

Teladoc Health News Roundup

Investors following TDOC have been watching these news items:

  • Positive Sentiment: Zacks raised its FY2026 EPS estimate to a loss of $0.87 from $0.89 and its FY2027 estimate to a loss of $0.91 from $0.98. It also improved several quarterly forecasts, including Q3 2027, from a loss of $0.26 to $0.17 per share. Teladoc Health analyst estimates
  • Neutral Sentiment: Truist raised its price target to $9 from $8 but maintained a Hold rating, signaling a higher valuation view without a change to its recommendation. Truist price-target update
  • Negative Sentiment: Zacks lowered estimates for Q4 2026, Q4 2027, Q1 2028, and FY2028. Its revised FY2028 forecast is a loss of $0.64 per share, compared with $0.63 previously. These cuts temper the positive revisions and keep the overall outlook mixed. Teladoc Health analyst estimates

Teladoc Health Company Profile

(Get Free Report)

Teladoc Health, Inc. provides virtual healthcare services through a digital platform that connects individuals with clinicians and other health professionals. Its offerings include virtual primary and specialty care, mental health services, and support for managing chronic conditions. The company serves members in the United States and internationally, with services and availability varying by market. Its consumer mental health services include BetterHelp, while its chronic-care programs draw on technology and services developed by Livongo, which Teladoc acquired in 2020.

Featured Articles

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.